Arkolith/Insider Trading/SPRY/Form 4

Dorsey Brian

Chief Operating OfficerARS Pharmaceuticals, Inc. (SPRY) · full profile →Form 4 · filed Nov 14, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$190K
Net Open-Market Flow
-$190K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 13, 2025Option exercise(M)22K$0.64$14K33K
Nov 13, 2025Sell(S)22K$8.71$190K11K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 13, 2025Option exercise(M)22K—$00

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001380762-25-000005) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for ARS Pharmaceuticals, Inc.

Build

Ask your agent about SPRY insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001380762-25-000005"
Ask your agent
Use Arkolith to summarize insider buying and selling at ARS Pharmaceuticals, Inc.
over the last 90 days and cite the filings.